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ABSTRACT
The clinical spectrum of coronavirus disease 2019 (COVID-19) infection ranges from asymptomatic infection to severe
pneumonia with respiratory failure and even death. More severe cases with higher mortality have been reported in older
patients and in those with chronic illness such as hypertension, diabetes or cardiovascular diseases. In this regard, patients
with chronic kidney disease (CKD) have a higher rate of all-type infections and cardiovascular disease than the general
population. A markedly altered immune system and immunosuppressed state may predispose CKD patients to infectious
complications. Likewise, they have a state of chronic systemic inflammation that may increase their morbidity and
mortality. In this review we discuss the chronic immunologic changes observed in CKD patients, the risk of COVID-19
infections and the clinical implications for and specific COVID-19 therapy in CKD patients. Indeed, the risk for severe
COVID-19 is 3-fold higher in CKD than in non-CKD patients; CKD is 12-fold more frequent in intensive care unit than in
non-hospitalized COVID-19 patients, and this ratio is higher than for diabetes or cardiovascular disease; and acute COVID-
19 mortality is 15–25% for haemodialysis patients even when not developing pneumonia.
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INTRODUCTION
Since the first reports of some cases of atypical pneumonia
in China in December 2019 and the extreme measures
adopted by the Chinese government in closing the city of
Wuhan (the focus of the problem), everything rapidly
changed. The causative agent of this respiratory disease was
identified as a novel coronavirus [1], called severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), and the
disease was termed coronavirus disease 2019 (COVID-19) by
the World Health Organization [2].
Coronaviruses were described for the first time in 1966 by
Tyrell and Bynoe, who cultivated the viruses from patients with
common colds [3]. They are enveloped, positive, single-stranded
large RNA viruses that not only infect humans, but also a wide
range of animals (bats, pangolins, cats, pigs and birds, among
others). The genome size varies between 26 and 32 kb. Based on
their morphology as spherical virions with a core shell and
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surface projections resembling a solar corona, they were termed
coronaviruses. At present, four subfamilies are recognized: a-,
b-, c- and d-coronaviruses [4]. SARS-CoV-2 belongs to the B line-
age of b-coronaviruses and is closely related to the SARS-CoV.
The major four structural genes encode the nucleocapsid pro-
tein (N), the spike protein (S), a small membrane protein (SM)
and the membrane glycoprotein (M), with an additional mem-
brane glycoprotein (HE) occurring in the HCoV-OC43 and HKU1
b-coronaviruses [5].
The clinical spectrum of COVID-19 infection is very variable,
ranging from asymptomatic infection, anosmia, ageusia or mi-
nor upper respiratory tract illness to severe pneumonia with re-
spiratory failure and even death [6]. Diarrhoea and cutaneous
and thrombotic manifestations were recently described [7, 8].
More severe cases with higher rates of mortality have been
reported in older patients and in those with chronic illness such
as cardiovascular disease, hypertension or diabetes. However,
deaths have also occurred in previously healthy young patients.
Patients with chronic kidney disease (CKD) are expected to be at
higher risk of severe disease since their rate of all-type infec-
tions and the prevalence of cardiovascular disease are higher
than in the general population. Marked alterations in the im-
mune system have been reported in CKD patients, leading to an
immunosuppressed state and frequent infectious complica-
tions. Likewise, chronic systemic inflammation may also con-
tribute to higher morbidity and mortality in CKD patients [9]. In
this review we discuss the pathogenesis of COVID-19, the
chronic immunologic changes observed in CKD patients and the
risk of COVID-19 and the clinical implications for CKD patients
(Table 1).
COVID-19 PATHOGENESIS
For most patients, COVID-19 will affect mainly the upper and
lower respiratory tract. The primary mode of infection is
human-to-human transmission through close contact, which
occurs via spraying droplets from an infected individual
through coughing or sneezing. Additionally, surfaces are
thought to retain the virus for variable periods of time, depend-
ing on their nature [10]. COVID-19 has an asymptomatic incuba-
tion period of 2–14 days during which the virus can be
transmitted [11].
After entering the lungs, COVID-19 infects cells expressing
certain cell surface receptors such as angiotensin-converting
enzyme 2 (ACE2; e.g. alveolar type 2 cells) or CD147 [also known
as basigin, extracellular matrix metalloproteinase inducer
(EMMPRIN) and leukocyte activation antigen M6], which besides
lung cells, is also expressed in kidney tubular cells, among
others [11, 12] (https://www.proteinatlas.org/ENSG00000172270-
BSG/tissue). In healthy individuals, the innate immune re-
sponse against viral infection relies heavily on interferon (IFN)
type I responses and its downstream cascade that culminates in
controlling viral replication and induction of effective adaptive
immune response [13]. Coronaviruses may dampen the
antiviral IFN type I effect, resulting in uncontrolled viral replica-
tion, with the consequent influx of neutrophils and monocytes/
macrophages and hyperproduction of pro-inflammatory cyto-
kines, the so-called cytokine storm. Thus oxidative stress and
inflammation are crucial for defence against COVID-19 infec-
tion, but they may be deleterious if not properly regulated [14].
Specific lymphocyte T helper (Th1/Th17) activation may inten-
sify inflammatory responses. Severe COVID-19 is characterized
by severe lymphopaenia that is associated with an increased
risk of death [15]. The high mortality of patients with severe
lymphopaenia may reflect resistance to currently available ex-
perimental therapies. Lymphocyte depletion is thought to im-
pair antiviral defences and there have been attempts, discussed
below, at boosting these defences. Natural killer (NK) cells are
essential for defence against virus infections in general, and as
discussed below, some cell-based therapeutic approaches aim
at increasing their efficacy. They are thought to be activated in
COVID-19 and may contribute to both viral clearance and tissue
injury. Indeed, there is profound depletion of NK cells [16].
There is little information on T regulatory cells (Tregs) and
COVID-19. In one report, patients with COVID-19 had lower
numbers of Tregs, and this was more obvious in severe cases
[15]. Regarding a potential role of Tregs in disease pathogenesis,
there is information from other coronavirus infections. Thus, in
murine models of central nervous system infection, Tregs lim-
ited T cell–mediated tissue damage without impairing viral
clearance [17]. Meanwhile, B and plasma cells produce specific
antibodies that may help neutralize SARS-CoV-2. Both uncon-
trolled viral replication and the cytokine storm are thought to
contribute to disease pathogenesis, as illustrated by therapeutic
trials of both antiviral drugs and tocilizumab [neutralizing anti-
interleukin-6 (IL-6) antibody; NCT04317092].
Additionally, the findings of endothelial cell injury and
thrombotic microangiopathy have raised the spectrum of com-
plement involvement and triggered the use of anticomplement
strategies [18, 19]. In case reports, both the anticomplement C5
antibody eculizumab [20] and the complement C3 inhibitor
AMY-101 (Amyndas Pharmaceuticals, Philadelphia, PA, USA)
[21] were apparently effective in COVID-19 and an eculizumab
clinical trial is ongoing (NCT04288713).
At present, the mortality rate of COVID-19 worldwide is
2.4% of diagnosed cases. SARS-CoV-2 infection causes both
pulmonary and systemic severe inflammation, leading to multi-
organ dysfunction. Acute respiratory distress syndrome and re-
spiratory failure, sepsis and heart failure and thrombotic
complications have been reported as the most common causes
of death [22]. Mortality is higher in elderly people and those
with underlying health conditions such as hypertension, cardio-
vascular disease and diabetes [23]. The case fatality rate during
the first week of the epidemic was 0.15% [95% confidence inter-
val (CI) 0.12–0.18)] in mainland China, excluding the city of
Wuhan, in which this estimation was 5.25% (95% CI 4.98–5.51)
[24]. Outside China, the USA, Italy and Spain have the highest
mortality rates. The mortality rate will depend on testing
Table 1. COVID-19 in the CKD population
Key points: the COVID-19 pandemic and the CKD population
Decreased kidney function causes marked alterations in the immune system.
CKD patients are prone to develop all-cause infections.
CKD represents a risk factor for COVID-19 complications.
Causal conditions for CKD (hypertension, DM and CVD) are risk factors for COVID-19 mortality.
Special measures must be taken in CKD Stage 5 on dialysis and renal transplant patients.
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policies (it will be higher when just severely ill patients that are
hospitalized are tested) as well as on the overwhelming of
healthcare facilities [mortality shoots up once hospitals run out
of ventilators or intensive care unit (ICU) beds].
In a retrospective, multicentre Chinese cohort study, older
age, D-dimer levels >1 lg/mL and higher Sequential Organ
Failure Assessment scores on admission were associated with
higher odds of in-hospital death [6]. Furthermore, elevated se-
rum levels of IL-6, high-sensitivity cardiac troponin I, lactate de-
hydrogenase and lymphopaenia were more commonly seen in
severe COVID-19-affected patients. The age-dependent defects
in T and B cell function and the excess production of type 2
cytokines could lead to a deficiency in the control of viral repli-
cation and/or more prolonged and intense pro-inflammatory
responses, potentially leading to poor outcome [6]. In another
small study of 68 hospitalized patients, the risk of death was
higher in patients with cardiovascular disease. Older age, the
presence of underlying diseases, secondary infections and ele-
vated serum inflammatory cytokines were associated with in-
creased mortality. They suggested that COVID-19 mortality
might be due to virus-activated ‘cytokine storm syndrome’ or
fulminant myocarditis [25]. Further reports have linked cardio-
vascular disease with a higher risk of mortality [26]. Higher body
mass index is more often seen in critical patients and non-
survivors. Aggravating factors include fulminant inflammation,
lactic acid accumulation and thrombotic events [26]. High ferri-
tin has recently emerged as a severe disease indicator [27].
CKD AND COVID-19
At present, the literature regarding CKD and COVID-19 is scarce.
A PubMed search for ‘(CKD OR chronic kidney disease) and
(COVID-19 OR SARS-CoV-2)’ performed on 10 April 2020 dis-
closed only one relevant citation, corresponding to a letter to
the editor meta-analysis that recorded a higher risk of severe
COVID-19 disease in CKD patients [odds ratio 3.03 (95% CI 1.09–
8.47), I2¼ 0.0%, Cochran’s Q, P¼ 0.84] after analysing four studies
including 1389 COVID-19 patients, among which 273 (19.7%) had
severe disease [28]. An analysis of 7162 laboratory-confirmed
COVID-19 cases in the USA confirmed that CKD was 12-fold
more frequent in those with ICU admission and 9-fold more fre-
quent in hospitalized, non-ICU COVID-19 patients than in those
not hospitalized. The increased prevalence of CKD in ICU ad-
mission was higher than the prevalence of other pre-existing
conditions (ratio of prevalence in ICU versus not hospitalized
patients ranged from 2- to 6.7-fold; Figure 1A and B), although
these data were not adjusted for covariates [29]. In an ‘in press’
report, evidence of kidney disease at admission in 701 patients
hospitalized for COVID-19 was associated with a significantly
higher risk for in-hospital death in an adjusted analysis. This
ranged from 1.8-fold for proteinuria to 2.1-fold for elevated se-
rum creatinine and 3-fold for haematuria. The risk associated
with acute kidney injury (AKI) ranged from 1.9- to 4.4-fold
higher depending on AKI severity [30]. However, the study de-
sign could not distinguish between pre-existent CKD and
COVID-19-associated kidney injury. Hence CKD patients should
be included in the COVID-19 high-risk groups. Additionally, the
main causes of CKD are cardiovascular, hypertension and/or di-
abetes related. In this regard, a preprint report, not yet peer-
reviewed, of a small study of 37 COVID-19 haemodialysis (HD)
patients from Wuhan observed lower peripheral blood T cells,
Th cells, killer T cells and NK cells than in the infected general
population as well as remarkably lower serum levels of inflam-
matory cytokines than other COVID-19 patients [31]. Of note,
72% of these patients presented with no obvious symptoms.
This could mask the suspicion of active disease and transform
them into carriers and transmitters of the virus. During a short
follow-up (<2 months), 6/37 (16%) COVID-19 HD patients and 1/
193 (0.5%) COVID-19-free HD patents died. The high mortality
was not related to respiratory causes, which would be in line
with the current understanding of the pathogenesis of lung in-
jury (mainly inflammation mediated) and the low evidence of
inflammation observed. How to explain the high mortality
then? This is not surprising either, given that viral (e.g. influ-
enza) or severe infection is associated with an increased risk of
cardiovascular events both in the general population and in
CKD patients [32, 33]. The Wuhan report is in line with prelimi-
nary data from the national registry of COVID-19 from the
Spanish Society of Nephrology that includes 637 patients to
date (409 patients on HD, 203 transplanted patients and 25
patients on peritoneal dialysis) and shows a mortality rate of
21% (https://mailchi.mp/senefro/registro-epidemiolgico-vhc-
vhb-vih-1314521; date last accessed 8 April 2020).
KIDNEY INVOLVEMENT IN COVID-19
Beyond respiratory cells, other organs might be affected by
SARS-CoV-2, including the kidneys, ileum and heart, especially
in the presence of viraemia. Thus cultured renal proximal tubu-
lar epithelial cells, glomerular mesangial cells and podocytes
express ACE2 on their surface and may represent another target
for COVID-19 [34]. Additionally, CD147 is expressed in the baso-






























































FIGURE 1: (A) Prevalence of CKD according to severity of COVID-19. There is a
gradient in CKD prevalence from the more severe (ICU patients) to the less se-
vere patients (not hospitalized). (B) Prevalence of CKD and additional pre-exist-
ing conditions according to COVID-19 severity. The ratio of the prevalence in
ICU patients versus the prevalence in non-hospitalized patients is presented.
*Conditions in which <100 patients were analysed. Data were obtained from
CDC COVID-19 Response Team [29].
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As the main site of ACE2 expression is the brush border of
proximal tubular cells (https://www.proteinatlas.org/
ENSG00000130234-ACE2/tissue/kidney; Figure 2B), it is likely
that in the absence of viruria (and the few reports that
addressed this issue did not find it) or glomerular filtration of
the virus (unlikely given its 70–90 nm size), CD147 may repre-
sent the key receptorfor kidney involvement of the virus. In cul-
ture, SARS-CoV, the cause of SARS, leads to productive infection
in immortalized proximal tubular cells but not glomerular
mesangial cell or podocytes [35]. Although the kidneys have
higher ACE2 activity than the lungs, heart and pancreas [36],
heart and arterial smooth muscle cells also express ACE2 and
may theoretically become infected.
Circulating and local renin–angiotensin–aldosterone system
(RAAS; including ACE2) are activated in kidney disease [37]. In
this regard, in different models of experimental diabetic ne-
phropathy, local kidney ACE2 is increased, reflecting largely tu-
bular cells that account for ~90% of kidney mass [38]. One may
speculate that increased tubular cell ACE2 as a consequence of
pre-existent pathological conditions may facilitate SARS-CoV-2
infection of tubular cells. However, as data regarding the ACE2/
SARS-CoV-2 interaction in kidney disease are scarce, it would
be premature to speculate about intrarenal RAAS modulation of
SARS-CoV-2 infection at this point.
AKI, proteinuria and haematuria have been reported in
COVID-19-positive patients. AKI is usually observed in the
context of systemic organ failure [39]. Among 701 patients with
COVID-19 admitted in a Wuhan hospital, at admission 44% had
proteinuria, 27% had haematuria and the prevalence of elevated
serum creatinine, elevated urea and estimated glomerular fil-
tration rate (eGFR) <60 mL/min/1.73 m2 was 14, 13 and 13%, re-
spectively. Additionally, 5% of patients developed AKI [39].
However, as discussed above, the study design could not distin-
guish between pre-existent CKD and COVID-19-associated kid-
ney injury and there is evidence that CKD patients are at higher
risk of severe disease requiring hospitalization.
It is currently unclear to what extent the virus directly dam-
ages renal cells or whether kidney injury is mainly secondary to
the cytokine storm syndrome [40]. Understanding the key
mechanisms of kidney injury in COVID-19 will have therapeutic
implications. The cytokine storm has the potential to directly
cause AKI, as supported by research in sepsis, endotoxemia, the
direct parenteral administration of inflammatory cytokines and
interventional studies [41]. It may be speculated that the inter-
action of both processes may be most damaging: previously in-
jured infected cells may be more sensitive to a deleterious
cytokine environment. Thus there is morphological and immu-
nohistochemical evidence of SARS-CoV-2 infection of tubular
cells and podocytes. Potentially the contribution to kidney in-
jury may differ at different stages of the natural history, with vi-
ral-induced tissue injury more prominent in early stages, when
lymphopaenia may contribute to viral expansion, and a more
FIGURE 2: Kidney expression of cell receptors for SARS-CoV-2 according to the Protein Atlas. (A) CD147 immunostaining in normal human kidney (https://www.protei
natlas.org/ENSG00000172270-BSG/tissue/kidney#img). (B) ACE2 immunostaining in normal human kidney (https://www.proteinatlas.org/ENSG00000130234-ACE2/tis
sue/kidney). Note than CD147 is mainly expressed in the basolateral membrane of proximal and distal tubular cells while the main site of ACE2 expression is the brush
border in the luminal side of proximal tubular cells.
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prominent role of inflammation in more advanced stages. A
post-mortem report in COVID-19 patients who developed kid-
ney failure suggests that coronaviruses directly infect kidney tu-
bular cells, inducing acute tubular damage [35]. Moreover, there
was CD68þ macrophage infiltration and complement C5b-9 de-
position. Data are available for 26 autopsies of patients with
COVID-19 dying from respiratory failure associated with multi-
ple organ dysfunction syndrome, of whom 9 had developed in-
creased serum creatinine and/or new-onset proteinuria. There
was diffuse proximal tubule injury and red blood cell casts.
Electron microscopy showed clusters of coronavirus particles in
the tubular epithelium and podocyte anti-SARS-CoV nucleopro-
tein-stained tubules [42]. Of note, no viral load of SARS-CoV-2 in
urine samples was found in the few studies that searched for it
in a small number of patients [43–45].
There is evidence for several potential mechanisms of kid-
ney injury, potentially depending on the severity of infection,
magnitude of the inflammatory response and even genetic
background. The most common mechanism based on both clin-
ical characteristics and histological studies is an acute tubular
necrosis form of AKI [42]. However, complement-mediated mi-
crovascular injury, rhabdomyolysis-associated kidney injury
and collapsing glomerulopathy associated with apolipoprotein
L1 risk variants have been described, among others [19, 46].
CKD, IMMUNE DYSFUNCTION AND COVID-19
CKD causes marked alterations in the immune system, includ-
ing persistent systemic inflammation and acquired immuno-
suppression [47] (Figure 3). The most common alterations in the
immune system in CKD patients are characterized by B and T
cell phagocytic dysfunction and increased concentrations of
pro-inflammatory cytokines and inflammatory monocytes [5,
48]. These alterations progress as renal function declines.
Regarding immune dysfunction in CKD, neutrophil function is
decreased in pre-dialysis and dialysis patients [49]. Likewise, B
lymphocytes of advanced CKD patients have an increased rate
of apoptosis that may contribute to B lymphopaenia [50]. T cells
from CKD patients have an aberrant state of early activation.
Activated T cells may be driven to apoptosis, thereby contribut-
ing to T lymphopaenia, progressive immunodeficiency and the
increased risk of infection observed in these patients [51].
Persistent inflammation, per se, is a risk factor for progression of
CKD and cardiovascular disease [52]. Multiple actors contribute
to chronic inflammation in CKD, including patient-related fac-
tors, oxidative stress, infections and HD-related factors such as
biocompatibility and dialysate quality [53]. Thus there was a
correlation between the presence of microorganism DNA/RNA
in the dialysate and oxidative stress and serum C-reactive pro-
tein and IL-6 [53].
PREVENTION AND TREATMENT OF COVID-19
IN CKD
At present, there is no vaccine against COVID-19, although mul-
tiple human trials are ongoing (e.g. NCT04299724, NCT04276896,
NCT04334980 and NCT04283461, among others). Moreover,
there is no approved therapy for COVID-19 and all current ther-
apies should be considered experimental. Thus, although clini-
cal trials of chemoprophylaxis are also ongoing (e.g.
NCT04328285, NCT04330495, NCT04304053, NCT04318015), pre-
vention relies mainly on social isolation and preventive
hygienic measures as recommended by nephrological societies
for HD and transplanted patients [39, 54, 55].
There was some initial controversy regarding the need to
stop RAS blockade, which is widely prescribed to CKD patients.
ACE2 expression is increased in diabetes and treatment with
ACE inhibitors and angiotensin II receptor blockers(ARBs)
increases ACE2 expression [56, 57]. It was thus hypothesized
that RAS blockade–induced ACE2 expression may facilitate
COVID-19 infection [56]. Conversely, since ACE2 protects from
experimental lung injury and recombinant ACE2 is undergoing
clinical trials for acute respiratory distress syndrome (28877748,
NCT00886353), it has been hypothesized that RAS blockade
should be part of the therapeutic regimen for COVID-19 in order
to increase ACE2 expression and its potential lung-protective
function [58]. There are no data regarding which of these medi-
cations (ACE inhibitors or ARBs) are better in COVID-19 patients.
In a multicentre retrospective evaluation of 511 patients with
COVID-19, in elderly (age >65 years) patients with hypertension,
the risk of severe disease was significantly lower in patients re-
ceiving ARBs. However, in this older group of patients, only 10
were on ARBs [59]. In any case, there is an ongoing clinical trial
of valsartan for prevention of acute respiratory distress syn-
drome in hospitalized patients with COVID-19 (NCT04335786).
In the absence of definitive evidence, some centres have opted
for stopping RAS blockade in COVID-19 patients, while others
follow clinical guidelines. In this regard, position statements
from major societies have emphasized the lack of clinical evi-
dence that RAS blockade is deleterious for COVID-19 patients
and the overwhelming evidence that stopping RAS blockade





data support the safety of RAS blockade in COVID-19 [60, 61].
When RAS blockade is prescribed for CKD from hypertension
only and the patient is anxious because of social media reports,
RAS blockade may be more safely changed than in cardiovascu-
lar disease patients.
Once CKD patients become infected, they should be quaran-
tined and, if on HD, dialyzed by fully protected personnel and
separated from non-COVID-19 patients, including transport to
the HD facility, while in the facitlity and back home. Criteria for
hospital admission are very variable, depending on whether
hospitals are overloaded by COVID-19. In general, patients with
low oxygen saturation or bilateral pneumonia on chest X-ray
should be hospitalized. There is general agreement on support-
ive therapy. Thus adequate oxygenation, euvolemic state sur-
veillance, haemodynamic support and all those measures
destined to prevent AKI or rapid progression of CKD should be
considered in renal disease patients [39]. However, there is wide
variability of therapeutic approaches for COVID-19-positive
patients (Table 2). This is related to the lack of approved thera-
pies. This variability includes decisions about treatment of indi-
viduals that are not hospitalized. In this regard, in Spain, all
inpatients receive some therapy, but this is not always the case
for outpatients, even those with pneumonia. Potential compo-
nents of the therapeutic cocktail in milder disease include anti-
viral drugs, non-antiviral drugs that may decrease viral
replication and low molecular weight heparin. Hospitalized
patients usually have hyperinflammation and may receive dif-
ferent combinations of anti-inflammatory agents such as ste-
roids or anti-interleukin agents on top of the medication for
milder cases. Thus Table 1 presents potential alternatives for
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therapy, but not all drugs are prescribed to the same individual.
Generally speaking, therapy for COVID-19-positive patients
with CKD is the same as in the general population.
Drugs targeting the virus
Aerosolized IFN-a and lopinavir/ritonavir showed some benefit
in a Chinese trial (ChiCTR2000029308) but no benefit beyond the
standard care treatments in another report [65]. Similarly, the
efficacy of chloroquine phosphate and remdesivir against
COVID-19 has been tested in human cells and showed inhibi-
tory properties for the virus [66]. Remdesivir was recently (1
May 2020) authorized for emergency use in COVID-19 by the US
Food and Drug Administration based on preliminary clinical
trial results [67]. Moreover, hydroxychloroquine plus azithromy-
cin decreased SARS-CoV-2 viral load in COVID-19 patients [68].
However, this combination may increase the risk of long QT–as-
sociated arrhythmia.
Drugs targeting inflammation
Immunosuppressive treatment with short-term systemic corti-
costeroids or monoclonal antibodies may decrease severe in-
flammation [63]. Ongoing trials with convalescent plasma have
shown that early application in patients with COVID-19 could
accelerate clinical recovery [69]. Arguments for the use of
cyclosporine A include in vitro data showing inhibition of coro-
navirus replication, as this requires peptidyl-prolyl cis-trans
isomerase activity of cyclophilin [70, 71], as well as evidence of
its efficacy in haemophagocytic lymphohistiocytosis, which
may be a complication of COVID-19 [72]. However, it remains an
immunosuppressive and nephrotoxic agent and protocols for
haemophagocytic lymphohistiocytosis suggest a delayed initia-
tion of cyclosporine A not compatible with the time course of
COVID-19.
Drugs targeting complications
Prophylactic low molecular weight heparin is the latest addition
to the standard therapeutic package for COVID-19. Thus, be-
yond venous thrombosis due to inactivity, large vessel arterial
thrombi and small vessel thrombi have been observed.
Recently, anti-phospholipid antibodies were described [73].
Future therapeutic approaches
As discussed above, another interesting approach in COVID-19
is to block the early stages of SARS-CoV-2 infection using hu-
man recombinant soluble ACE2, and clinical trials are ongoing
[74, 75]. Very recently, investigators from Sweden, Canada,
Spain and Austria described this new approach to the infection
[76]. Infection of human blood vessels and kidney organoids by
A B C
D
FIGURE 3: Interaction between SARS-CoV-2 and CKD. (A) Infection by SARS-CoV-2 results in viral entry into cells and viral replication, causing tissue injury. Tissue in-
jury is aggravated by a severe inflammatory response, eventually leading to death in some patients. (B) CKD is characterized by both evidence of immune deficiency,
which may facilitate viral replication and expansion, and systemic inflammation, which may aggravate the hyperinflammation observed in more severe COVID-19
patients. (C) CKD is frequently associated with comorbidities that are dependent (e.g. anaemia, malnutrition and vitamin D deficiency) or associated (e.g. cardiovascu-
lar disease and diabetes) with CKD. These comorbidities may also contribute to more severe disease, leading to death. Thus there is a biological plausibility supporting
the empirical evidence of a higher mortality of COVID-19 in CKD patients. (D) Current therapy is aimed at decreasing viral replication and boosting antiviral defences,
limiting hyperinflammation and supporting measures and thrombosis prevention. Currently these measures are similar for CKD and non-CKD patients. Research is
needed for optimization and individualization of the therapeutic approach to the CKD state.
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SARS-CoV-2 was significantly inhibited by recombinant soluble
ACE2 (rACE2) at the early stages of infection. Soluble rACE2
competes with cell membrane ACE2 for virus binding. Currently
a Phase 2 trial has started in 200 COVID-19 patients in Germany
and Austria (NCT04287686). Additionally, a Chinese trial is eval-
uating NKG2D-ACE2 chimeric antigen receptor–NK cells
(NCT04324996). NKG2D is an activating receptor of NK cells,
which can recognize and thus clear virus-infected cells.
Vitamin D has important functions beyond those of bone
and mineral homeostasis that include modulation of the innate
and adaptive immune responses. Vitamin D has pleiotropic
effects in the immune system and documented benefits in
chronic inflammatory states such as those observed in CKD
patients [77]. To date, the benefit of vitamin D supplementation
in COVID-19 patients has not been demonstrated; nevertheless,
a clinical trial has been designed in Spain (NCT04334005).
It was recently postulated that extracorporeal membrane ox-
ygenation may help patients through non-specific removal of
circulating pro-inflammatory cytokines that cause the cytokine
storm [78]. Therefore, continuous renal replacement therapies
may play an important role in patients with COVID-19 and sep-
sis syndrome.
CONCLUSIONS
In conclusion, CKD patients are at an increased risk of develop-
ing severe COVID-19. Moreover, the mortality rate appears to be
higher than in the general population and not always directly
related to the severity of pulmonary compromise. This is not
surprising, given that viral (e.g. influenza) or severe infection is
associated with an increased risk of cardiovascular events both
in the general population and in CKD patients [32, 33].
Additionally, CKD patients frequently have cardiovascular and
diabetes comorbidities that may independently predispose to
severe COVID-19. Given the absence of vaccine or approved
therapy, nephrologists should advise CKD patients to follow so-
cial isolation recommendations directed at high-risk patients.
These should be extended to dialysis units, where a high index
of suspicion and testing for COVID-19 should be implemented.
Additionally, if healthcare systems are overwhelmed by the
pandemic, nephrologists should fight so that, despite the higher
risk, CKD is not considered a comorbidity that weighs down the
patient’s chances to access ICU care or a respirator.
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